Evidence map›Paper›PMID 40765673›Full record

ReviewClinics in colon and rectal surgery2025

Personalizing Perioperative Chemotherapy in Colon Cancer.

Joyce H Pang, Charles A Baldi, Daniel O Herzig

Abstract readReview
In one paragraph

Review in Clinics in colon and rectal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joyce H PangDepartment of Surgery, Oregon Health and Science University, Portland, Oregon.
Charles A BaldiDepartment of Surgery, Oregon Health and Science University, Portland, Oregon.
Daniel O HerzigDepartment of Surgery, Oregon Health and Science University, Portland, Oregon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The traditional, surgery-first approach for colon cancer is increasingly challenged by our evolving understanding of tumor biology and a growing number of measurable tumor features that can help guide contemporary treatment plans. Certain tumor characteristics now make it practical to challenge locally advanced colon cancer with neoadjuvant chemotherapy or immunotherapy, and allow for targeted postoperative therapies. The contemporary data supporting these tailored approaches to integrating systemic therapy before or after resection are summarized in this article.

Indexed as

chemotherapycolon cancermicrosatellite instabilitynext-generation sequencing

Identifiers

PMID40765673
PMCPMC12321365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.